Savant Capital LLC Trims Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Savant Capital LLC decreased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 64.1% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 2,054 shares of the biopharmaceutical company’s stock after selling 3,667 shares during the quarter. Savant Capital LLC’s holdings in Regeneron Pharmaceuticals were worth $1,585,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Moors & Cabot Inc. grew its position in shares of Regeneron Pharmaceuticals by 10.1% during the 4th quarter. Moors & Cabot Inc. now owns 785 shares of the biopharmaceutical company’s stock worth $606,000 after buying an additional 72 shares in the last quarter. Huntington National Bank grew its position in shares of Regeneron Pharmaceuticals by 21.1% during the 4th quarter. Huntington National Bank now owns 642 shares of the biopharmaceutical company’s stock worth $496,000 after buying an additional 112 shares in the last quarter. Kingsview Wealth Management LLC grew its position in shares of Regeneron Pharmaceuticals by 4.0% during the 4th quarter. Kingsview Wealth Management LLC now owns 811 shares of the biopharmaceutical company’s stock worth $626,000 after buying an additional 31 shares in the last quarter. Texas Capital Bank Wealth Management Services Inc bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth $245,000. Finally, King Luther Capital Management Corp grew its position in shares of Regeneron Pharmaceuticals by 5.0% during the 4th quarter. King Luther Capital Management Corp now owns 948 shares of the biopharmaceutical company’s stock worth $732,000 after buying an additional 45 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $600.66 on Tuesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57. The company has a market cap of $63.50 billion, a PE ratio of 14.64, a P/E/G ratio of 1.36 and a beta of 0.25. The business has a 50-day simple moving average of $716.42 and a two-hundred day simple moving average of $744.46. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The firm had revenue of $3.61 billion during the quarter, compared to analysts’ expectations of $3.48 billion. During the same period last year, the business posted $8.22 earnings per share. The company’s revenue for the quarter was up 19.0% compared to the same quarter last year. As a group, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.25 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 4th. Investors of record on Wednesday, May 20th will be issued a dividend of $0.94 per share. The ex-dividend date of this dividend is Wednesday, May 20th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s payout ratio is 9.16%.

Insider Activity at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $705.24, for a total transaction of $70,524.00. Following the completion of the sale, the director owned 17,503 shares of the company’s stock, valued at $12,343,815.72. The trade was a 0.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. Weiss Ratings reissued a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Friday, March 27th. Truist Financial dropped their price target on Regeneron Pharmaceuticals from $796.00 to $778.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. Leerink Partners reissued a “market perform” rating and set a $641.00 price target (down from $792.00) on shares of Regeneron Pharmaceuticals in a research report on Monday, May 18th. Oppenheimer reaffirmed an “outperform” rating and set a $865.00 price objective (up from $750.00) on shares of Regeneron Pharmaceuticals in a research report on Monday, February 2nd. Finally, Royal Bank Of Canada dropped their price objective on Regeneron Pharmaceuticals from $762.00 to $707.00 and set a “sector perform” rating on the stock in a research report on Monday, May 18th. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $792.65.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.